Attached files
file | filename |
---|---|
8-K - FORM 8-K - NxStage Medical, Inc. | b87554e8vk.htm |
Exhibit 99.1
NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
Highlights:
- Revenue Increases to $53.8 million, up 22% from Q210
- Home Market Increases to $27.0 million, up 30% from Q210
- Gross Margin Increases to 35%, up from 31% in Q210
- Company Announces Extension of Agreement in the Home Market with
Large Customer
LAWRENCE, Mass., August 3, 2011 NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of
innovative dialysis products, today reported record financial results for the second quarter of
2011 ended June 30, 2011, with total revenue well above the top end of its guidance range.
Revenue for the second quarter of 2011 increased to $53.8 million, an increase of 22 percent when
compared with revenue of $44.0 million for the second quarter of 2010. The increase was driven by
strong performance across all three markets: Home, Critical Care and In-Center.
The Company grew Home revenue to $27.0 million for the second quarter of 2011, representing an
increase of 30 percent when compared with revenue of $20.8 million for the second quarter of 2010.
Critical Care revenue grew to $8.6 million for the second quarter of 2011, representing an increase
of 29 percent when compared with revenue of $6.7 million for the second quarter of 2010. Revenue
in the In-Center market, from the Companys Medisystems business, increased to $18.2 million for
the second quarter of 2011, representing an increase of 10 percent when compared with revenue of
$16.5 million for the second quarter of 2010.
Building on last quarters momentum, we delivered strong results across our business and topped
expectations, stated Jeffrey H. Burbank, CEO of NxStage Medical, Inc. With the first and only
truly portable hemodialysis system cleared for home use by the FDA and similar competition still a
number of years away, we see significant opportunities for growth, continued innovation and
expansion within the Home. Given the strength that were seeing across all markets and the growth
in our opportunity pipeline, were raising our revenue outlook for 2011 to a range of $210 million
to $215 million.
NxStage reported a net loss of $5.6 million, or ($0.10) per share, for the second quarter of 2011
compared with a net loss of $8.3 million, or ($0.17) per share, for the second quarter of 2010.
For the second quarter of 2011, the Company reported Adjusted EBITDA, adjusted for stock-based
compensation, deferred revenue recognized, manufacturing transition costs and other non-cash
expenses of $1.8 million, compared with an Adjusted EBITDA loss of $0.2 million in the second
quarter of 2010. (See the exhibits for a reconciliation of this non-GAAP measure.)
NxStage announced that it recently concluded its
renegotiation of its United States home market
agreement with one of its largest customers and signed an amendment to that agreement, extending the term
to December 31, 2012, and up to one additional year thereafter. The amended agreement covers the
use of NxStages products for home hemodialysis.
Separately, NxStage announced that pursuant to its agreement with DaVita, for the period ended June 30,
2011, DaVita achieved System One home patient growth targets that entitled it to become vested in
warrants to purchase 250,000 shares of NxStage common stock.
Guidance:
For the third quarter of 2011, the Company is forecasting revenue to be within a range of $53.5 to
$54.5 million. At this revenue level, the Company would expect a net loss in the range of $5.0 to
$6.0 million or ($0.09) to ($0.11) per share, and Adjusted EBITDA in the range of $1.0 to $2.0
million for the third quarter of 2011.
Supported by its strong performance in the first half of 2011, the Company now anticipates revenue
for the 2011 fiscal year to be in a range of $210 to $215 million, compared with its prior guidance
for revenues to be in a range of $205 to $213 million. The Company is maintaining its guidance for
a net loss in the range of $19 to $23 million or ($0.36) to ($0.43) per share, and for Adjusted
EBITDA to be in the range of $6.0 million to $10.0 million for the 2011 fiscal year. As a result
of the impact of unfavorable foreign exchange and the acceleration of the transition of our blood
tubing sets to in-house manufacturing, the Company expects fourth quarter gross margin percentage
to be at around the low end of its previously announced guidance of 38 to 42 percent.
This release contains a non-GAAP financial measure. A reconciliation of the Companys non-GAAP
financial measure to its most comparable GAAP financial measure is in the exhibits to this press
release.
Conference Call:
NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its second
quarter financial results. To listen to the conference call, please dial 800.510.9836 (domestic) or
617.614.3670 (international). The passcode is 68598834. The call will also be webcast LIVE and
can be accessed via the investor relations section of the Companys website at
www.nxstage.com/ir.cfm.
A replay of the conference call will be available 2 hours after the conclusion of the call through
August 10, 2011. To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international)
and enter passcode 87428332. An online archive of the conference call can be accessed via the
investor relations section of the Companys website at
www.nxstage.com/ir.cfm.
About NxStage
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence,
Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment
of ESRD and acute kidney failure. For more information on NxStage and its products, please visit
the companys website at www.nxstage.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words anticipate, believe, expect,
estimate, plan, and similar expressions are generally intended to identify forward-looking
statements. Examples of these forward-looking statements include statements as to the anticipated
demand for the Companys products, anticipated operating results, including revenues, loss, gross
margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All
forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond
NxStages control, which may cause actual results, performance, or achievements to differ
materially from anticipated results, performance or achievements, including market acceptance and
demand for NxStages products, growth in home and/or daily hemodialysis, unanticipated difficulties
in achieving operational efficiencies and cost reductions, changes in reimbursement for home and
daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing
patterns and preferences of our customers, including DaVita Inc., and certain other factors that
may affect future operating results and which are detailed in NxStages filings with the Securities
and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended March 31,
2011.
In addition, the statements in this press release represent NxStages expectations and beliefs as
of the date of this press release. NxStage anticipates that subsequent events and developments may
cause these expectations and beliefs to change. However, while NxStage may elect to update these
forward-looking statements at some point in the future, it specifically disclaims any obligation to
do so, whether as a result of new information, future events, or otherwise. These forward-looking
statements should not be relied upon as representing NxStages expectations or beliefs as of any
date subsequent to the date of this press release.
Contact:
Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com
Non-GAAP Financial Measure
The Company discloses a certain non-GAAP financial measure to supplement the Companys consolidated
financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or
an alternative for, generally accepted accounting principles in the United States and may be
different from similar non-GAAP financial measures used by other companies. The non-GAAP financial
measure disclosed by the Company is not meant to be considered superior to or a substitute for
results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA
adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs
and other non-cash expenses) to understand operational cash usage. The Company believes the non-GAAP
financial measure provides useful and supplementary information allowing investors greater
transparency to one measure used by management. The non-GAAP financial measure is meant to
supplement, and to be viewed in conjunction with, GAAP financial measures. The non-GAAP financial
measure is reconciled to the most comparable GAAP financial measure below.
NxStage Medical, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenues |
$ | 53,768 | $ | 44,008 | $ | 104,332 | $ | 84,416 | ||||||||
Cost of revenues |
34,903 | 30,246 | 67,434 | 58,841 | ||||||||||||
Gross profit |
18,865 | 13,762 | 36,898 | 25,575 | ||||||||||||
Operating expenses: |
||||||||||||||||
Selling and marketing |
9,369 | 8,565 | 18,579 | 16,582 | ||||||||||||
Research and development |
3,589 | 3,202 | 7,306 | 6,237 | ||||||||||||
Distribution |
4,431 | 3,632 | 8,589 | 7,043 | ||||||||||||
General and administrative |
5,460 | 5,643 | 11,042 | 10,581 | ||||||||||||
Total operating expenses |
22,849 | 21,042 | 45,516 | 40,443 | ||||||||||||
Loss from operations |
(3,984 | ) | (7,280 | ) | (8,618 | ) | (14,868 | ) | ||||||||
Other expense: |
||||||||||||||||
Interest expense |
(1,170 | ) | (1,148 | ) | (2,327 | ) | (2,256 | ) | ||||||||
Other (expense) income, net |
(170 | ) | 330 | (196 | ) | 213 | ||||||||||
(1,340 | ) | (818 | ) | (2,523 | ) | (2,043 | ) | |||||||||
Net loss before income taxes |
(5,324 | ) | (8,098 | ) | (11,141 | ) | (16,911 | ) | ||||||||
Provision for income taxes |
226 | 158 | 419 | 344 | ||||||||||||
Net loss |
$ | (5,550 | ) | $ | (8,256 | ) | $ | (11,560 | ) | $ | (17,255 | ) | ||||
Net loss per share, basic and diluted |
$ | (0.10 | ) | $ | (0.17 | ) | $ | (0.22 | ) | $ | (0.37 | ) | ||||
Weighted-average shares outstanding,
basic and diluted |
54,014 | 47,492 | 53,716 | 47,228 | ||||||||||||
NxStage Medical, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
June 30, | December 31, | |||||||
2011 | 2010 | |||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 100,426 | $ | 104,339 | ||||
Accounts receivable, net |
15,889 | 14,107 | ||||||
Inventory |
39,213 | 34,950 | ||||||
Prepaid expenses and other current assets |
2,475 | 2,084 | ||||||
Total current assets |
158,003 | 155,480 | ||||||
Property and equipment, net |
12,540 | 8,290 | ||||||
Field equipment, net |
13,036 | 13,660 | ||||||
Deferred cost of revenues |
40,458 | 40,081 | ||||||
Intangible assets, net |
24,013 | 25,412 | ||||||
Goodwill |
42,698 | 42,698 | ||||||
Other assets |
675 | 473 | ||||||
Total assets |
$ | 291,423 | $ | 286,094 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 22,620 | $ | 16,811 | ||||
Accrued expenses |
14,201 | 19,537 | ||||||
Current portion of long-term debt |
16 | 43 | ||||||
Total current liabilities |
36,837 | 36,391 | ||||||
Deferred revenues |
55,995 | 55,366 | ||||||
Long-term debt |
41,818 | 40,454 | ||||||
Other long-term liabilities |
5,639 | 1,754 | ||||||
Total liabilities |
140,289 | 133,965 | ||||||
Commitments and contingencies |
||||||||
Stockholders equity: |
||||||||
Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding
as of June 30, 2011 and December 31, 2010 |
| | ||||||
Common stock: par value $0.001, 100,000,000 shares authorized; 55,172,136 and 54,043,317 shares issued as of
June 30, 2011 and December 31, 2010, respecitvely |
55 | 53 | ||||||
Additional paid-in capital |
479,186 | 465,642 | ||||||
Accumulated deficit |
(319,986 | ) | (308,426 | ) | ||||
Accumulated other comprehensive income |
395 | 85 | ||||||
Treasury stock, at cost: 480,923 and 325,104 shares as of June 30, 2011 and December 31, 2010, respectively |
(8,516 | ) | (5,225 | ) | ||||
Total stockholders equity |
151,134 | 152,129 | ||||||
Total liabilities and stockholders equity |
$ | 291,423 | $ | 286,094 | ||||
NxStage Medical, Inc.
Cash Flows from Operating Activities
(in thousands)
(unaudited)
Cash Flows from Operating Activities
(in thousands)
(unaudited)
Six Months Ended | ||||||||
June 30, | ||||||||
2011 | 2010 | |||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ | (11,560 | ) | $ | (17,255 | ) | ||
Adjustments to reconcile net loss to net
cash used in operating activities: |
||||||||
Depreciation and amortization |
11,459 | 11,077 | ||||||
Stock-based compensation |
6,701 | 6,875 | ||||||
Other |
1,737 | 1,128 | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(1,753 | ) | (527 | ) | ||||
Inventory |
(13,363 | ) | (13,327 | ) | ||||
Prepaid expenses and other assets |
(546 | ) | (404 | ) | ||||
Accounts payable |
5,471 | (399 | ) | |||||
Accrued expenses and other liabilities |
(2,446 | ) | 3,060 | |||||
Deferred revenues |
629 | 8,745 | ||||||
Net cash used in operating activities |
$ | (3,671 | ) | $ | (1,027 | ) | ||
NxStage Medical, Inc.
Revenues by Segment
(in thousands)
Revenues by Segment
(in thousands)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
System One segment |
||||||||||||||||
Home |
$ | 27,013 | $ | 20,815 | $ | 53,058 | $ | 39,858 | ||||||||
Critical Care |
8,591 | 6,652 | 16,029 | 12,711 | ||||||||||||
Total System
One segment |
35,604 | 27,467 | 69,087 | 52,569 | ||||||||||||
In-Center segment |
18,164 | 16,541 | 35,245 | 31,847 | ||||||||||||
Total |
$ | 53,768 | $ | 44,008 | $ | 104,332 | $ | 84,416 | ||||||||
NxStage Medical, Inc.
Non-GAAP Financial Measures
(in millions)
(unaudited)
Non-GAAP Financial Measures
(in millions)
(unaudited)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net loss |
$ | (5.6 | ) | $ | (8.3 | ) | $ | (11.6 | ) | $ | (17.3 | ) | ||||
Less: Depreciation, amortization, interest, and taxes |
7.3 | 6.5 | 14.4 | 13.4 | ||||||||||||
Less: Adjusting items* |
0.1 | 1.6 | 0.1 | 2.4 | ||||||||||||
Adjusted EBITDA gain (loss) |
$ | 1.8 | $ | (0.2 | ) | $ | 2.9 | $ | (1.5 | ) | ||||||
* | Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses |
NxStage Medical, Inc.
Non-GAAP Financial Guidance
(amounts in millions)
Non-GAAP Financial Guidance
(amounts in millions)
Three Months Ended | ||||||||
September 30, 2011 | ||||||||
High | Low | |||||||
Estimate | Estimate | |||||||
Net loss |
$ | (5.0 | ) | $ | (6.0 | ) | ||
Less: Depreciation, amortization, interest, and taxes |
6.9 | 6.9 | ||||||
Less: Adjusting items* |
0.1 | 0.1 | ||||||
Adjusted EBITDA gain |
$ | 2.0 | $ | 1.0 | ||||
* | Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses |